<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238676</url>
  </required_header>
  <id_info>
    <org_study_id>Persica 002</org_study_id>
    <secondary_id>2018-004488-30</secondary_id>
    <nct_id>NCT04238676</nct_id>
  </id_info>
  <brief_title>Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain</brief_title>
  <official_title>A Phase 1b Study Investigating the Safety, Tolerability and Efficacy of PP353 in the Treatment of Patients With Chronic Low Back Pain Associated With Verterbral Body Endplate Bone Oedema (Modic 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Persica Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Micron Research Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Persica Pharmaceuticals Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b study to investigate the efficacy of PP353 compared to placebo in the treatment of
      chronic low back pain associated with bone oedema.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A 2-part study. In the first part the safety, tolerability and pharmacokinetics will be
      assessed in up to 6 participants. In the second part, the safety, tolerability and efficacy
      of PP353 will be assessed in up to 34 participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 20, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The pharmacist and injector will not be blinded to treatment allocation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in Low Back Pain Numerical Rating Scale (LBP NRS) score</measure>
    <time_frame>12 months</time_frame>
    <description>Each question will be assessed by the subject on an 11-point scale with 0 = &quot;no pain&quot; and 10 = &quot;the worst possible pain you can imagine.&quot;
The LBP NRS score throughout this protocol is defined as the average of the score of the three questions:
Low back pain intensity now
Worst low back pain intensity in the last 14 days
Average low back pain intensity over the last 14 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Low Back Pain Numerical Rating Scale (LBP NRS) score</measure>
    <time_frame>3, 6 &amp; 9 months</time_frame>
    <description>Each question will be assessed by the subject on an 11-point scale with 0 = &quot;no pain&quot; and 10 = &quot;the worst possible pain you can imagine.&quot;
The LBP NRS score throughout this protocol is defined as the average of the score of the three questions:
Low back pain intensity now
Worst low back pain intensity in the last 14 days
Average low back pain intensity over the last 14 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Roland Morris Disability Questionnaire-23 score</measure>
    <time_frame>3, 6, 9 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant improvement</measure>
    <time_frame>3, 6, 9 &amp;12 months</time_frame>
    <description>30 percent reduction from baseline in Roland Morris Disability Questionnaire-23 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Oswestry Disability Index</measure>
    <time_frame>3, 6 &amp; 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics - Tdur (duration above a prescribed threshold)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics - tmax (the time at which Cmax was apparent)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics - the area under the concentration versus time curve within a dosing interval</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics - Cmax (the maximum observed concentration)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics - t½ (the apparent terminal half-life)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics - CL/F (the systemic clearance calculated from plasma)</measure>
    <time_frame>11 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Low-back Pain</condition>
  <arm_group>
    <arm_group_label>PP353</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PP353-B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP353</intervention_name>
    <description>active administered by intradiscal injection</description>
    <arm_group_label>PP353</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PP353-B</intervention_name>
    <description>placebo administered by intradiscal injection</description>
    <arm_group_label>PP353-B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 30 and 65 years, inclusive.

          -  Chronic low back pain in the area associated with vertebral body endplate bone oedema
             (Modic 1) or vertebral body endplate bone oedema and fat (Modic 1 and 2) at a single
             lumbar level.

          -  Current episode of chronic low back pain has lasted for ≥ 6 months and &lt; 5 years at
             the time of randomisation.

          -  Bodyweight of ≥ 50 kg and ≤ 120 kg.

          -  Failure of standard of care therapies used by their treating physician

        Exclusion Criteria:

          -  The presence of a deformity associated with the disc

          -  A clear alternative cause for back pain

          -  Interventional back procedure in the 6 months prior to screening or major surgery in
             the 12 weeks prior to screening

          -  History of alcohol abuse or drugs of abuse in the past 2 years

          -  Any other significant illness

          -  Concomitant medications contraindicated with PP353
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Duncan McHale, MBBS MRCP</last_name>
    <role>Study Chair</role>
    <affiliation>Weatherden Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Operations and Project Director</last_name>
    <phone>+44 1227 910152</phone>
    <email>info@persicapharmaceuticals.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>Lancashire</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shiva Tripathi, MBBS MD FRCA</last_name>
      <phone>+44 1772 524185</phone>
      <email>Shiva.Tripathi@lthtr.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 16, 2020</study_first_submitted>
  <study_first_submitted_qc>January 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

